<DOC>
	<DOCNO>NCT02137707</DOCNO>
	<brief_summary>This study determine whether RRMS patient receive Gilenya link disease progression biologic marker .</brief_summary>
	<brief_title>Biologic Basis Multiple Sclerosis Disease Progression RRMS Patients Treated With Gilenya</brief_title>
	<detailed_description>The biologic basis determines disease progression multiple sclerosis ( MS ) patient remain defined . We propose long term study patient inflammatory activity disease expect controlled treatment , identify patient cohort whose disease deem stable patient whose disease deem progress . Once two group identify , possible ass whether difference biologic marker two group . These marker would potential use monitor disease progression predictor patient response drug treatment .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Deemed subject 's treating physician suitable candidate Gilenya therapy accordance Canadian Product Monograph Gilenya overall EDSS 7.0 currently receive Gilenya able perform adequately EDSS assessment cognitive test able undergo MRI able provide blood sample 65 year age 18 year age less 4 week discontinuation steroid treatment relapse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Multiple Sclerosis , Relapsing-Remitting</keyword>
	<keyword>Gilenya</keyword>
	<keyword>Fingolimod</keyword>
</DOC>